Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kelli J Glenn"'
Publikováno v:
Heliyon, Vol 9, Iss 8, Pp e18920- (2023)
Background: Cenobamate is an antiseizure medication used to treat partial-onset (focal) seizures. It is a molecule with one chiral center and a unique dual mechanism of action: enhancement of fast and slow inactivation of sodium channels with prefere
Externí odkaz:
https://doaj.org/article/a17f6eaf4506490690d818d4346e570a
Autor:
Stephen A. Greene, Charles Kwak, Marc Kamin, Laurent Vernillet, Kelli J. Glenn, Lana Gabriel, Hong Wook Kim
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 899-911 (2022)
Abstract This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; and omeprazole, CYP2C19
Externí odkaz:
https://doaj.org/article/bdb04ecb72b34ff8b87cbcec360d1a8f
Autor:
Stephen A. Greene, Charles Kwak, Marc Kamin, Laurent Vernillet, Kelli J. Glenn, Lana Gabriel, Hong Wook Kim
Publikováno v:
Clinical and Translational Science. 15:899-911
This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; and omeprazole, CYP2C19) in heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95a4e13811e390de37ddee5ad8c33e96
https://doi.org/10.1111/cts.13204
https://doi.org/10.1111/cts.13204
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 45:513-522
Cenobamate is an antiepileptic drug for the treatment of partial-onset seizures. The current study was designed to assess the mass balance and the metabolic profiling of cenobamate in humans. Absorption, metabolism, and excretion of cenobamate were i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360c4032d529254bf8b1ae90dca641c7
https://doi.org/10.1007/s13318-020-00615-7
https://doi.org/10.1007/s13318-020-00615-7
Autor:
Michelle Quinlan, Franck Picard, Dalila Sellami, Hildegard Boss, Jocelyn Zhou, Henry Castro, Kelli J Glenn
Publikováno v:
British Journal of Clinical Pharmacology. 82:1022-1029
Aims This study aimed to evaluate the impact of esomeprazole on the pharmacokinetics of sonidegib. Methods This Phase I study evaluated the impact of the proton pump inhibitor (PPI) esomeprazole on the oral absorption and pharmacokinetics (PKs) of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a67a37c060160d7cc0717ecd9e70a94c
https://doi.org/10.1111/bcp.13038
https://doi.org/10.1111/bcp.13038
Autor:
Chiranjivi Neupane, Jin Bong Park, Kelli J. Glenn, Byeong Hwa Jeon, Michiko Nakamura, Hyewon Shin, Ramesh Sharma, Susan M. Melnick, Il-Sung Jang
Publikováno v:
European Journal of Pharmacology. 879:173117
Cenobamate is a novel antiepileptic drug under investigation for use in patients with focal (partial-onset) seizures. To understand its potential molecular mechanism of action, the effects of cenobamate on GABAA-mediated currents and GABAA receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a828e2e8c60303178bb06496a94279bb
https://doi.org/10.1016/j.ejphar.2020.173117
https://doi.org/10.1016/j.ejphar.2020.173117
Publikováno v:
Drug Metabolism and Pharmacokinetics. 35:S69
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfe8f0401488c92ed52269aa2c2503eb
https://doi.org/10.1016/j.dmpk.2020.04.155
https://doi.org/10.1016/j.dmpk.2020.04.155
Autor:
Adrian J. Fretland, Mary Palacios, Dietrich Tuerck, Li J Yu, Jianguo Zhi, Micaela B. Reddy, Sazzad Hussain, Faye Vazvaei, Neil Parrott, Kelli J Glenn
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 46(8)
1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The purpose of the present studies was to investigate the cause of marked decrease in plasma exposure after repeated oral administratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4de6355ef99750d71696739caba152c
https://pubmed.ncbi.nlm.nih.gov/26586447
https://pubmed.ncbi.nlm.nih.gov/26586447